Redox-sensitive impairment of porcine coronary artery vasodilation by hypochlorite-modified LDL

Atherosclerosis

Volumn 190, Issue 2, 2007, Pages 330-337

  Plass, Christian A ^a   Schmid, Werner ^a   Holy, Erik W ^a   Kreatschitsch, Ursula ^a   Laggner, Hildegard ^a   Volf, Ivo ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Arterial relaxation; Atherosclerosis; Hypochlorite; Myeloperoxidase; Oxidative stress; Oxidized LDL; Vasotonus

Indexed keywords

ALBUMIN; APOLIPOPROTEIN B; CHLORAMINE DERIVATIVE; HYPOCHLORITE; METHIONINE; OXIDIZED LOW DENSITY LIPOPROTEIN; SUBSTANCE P;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DILATATION; CORONARY ARTERY DISEASE; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; CORONARY VESSELS; HUMANS; HYPOCHLOROUS ACID; KINETICS; LIPOPROTEINS, LDL; OXIDATION-REDUCTION; SWINE; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 33846120132     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.04.001     Document Type: Article

References (40)

1. Forstermann U., Mugge A., Alheid U., Haverich A., and Frolich J.C. Selective attenuation of endothelium-mediated vasodilation in atherosclerotic human coronary arteries. Circ Res 62 (1988) 185-190
2. Nabel E.G., Selwyn A.P., and Ganz P. Large coronary arteries in humans are responsive to changing blood flow: an endothelium-dependent mechanism that fails in patients with atherosclerosis. J Am Coll Cardiol 16 (1990) 349-356
3. Celermajer D.S., Sorensen K.E., Bull C., Robinson J., and Deanfield J.E. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 24 (1994) 1468-1474
4. Reddy K.G., Nair R.N., Sheehan H.M., and Hodgson J.M. Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J Am Coll Cardiol 23 (1994) 833-843
5. Zeiher A.M., Drexler H., Wollschlager H., and Just H. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 83 (1991) 391-401
6. Heinecke J.W. Oxidants and antioxidants in the pathogenesis of atherosclerosis: implications for the oxidized low density lipoprotein hypothesis. Atherosclerosis 141 (1998) 1-15
7. Stocker R., and Keaney J.F. Role of oxidative modifications in atherosclerosis. Physiol Rev 84 (2004) 1381-1478
8. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., and Witztum J.L. Beyond cholesterol Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320 (1989) 915-924
9. Deckert V., Persegol L., Viens L., et al. Inhibitors of arterial relaxation among components of human oxidized low-density lipoproteins. Cholesterol derivatives oxidized in position 7 are potent inhibitors of endothelium-dependent relaxation. Circulation 95 (1997) 723-731
10. Kugiyama K., Kerns S.A., Morrisett J.D., Roberts R., and Henry P.D. Impairment of endothelium-dependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 344 (1990) 160-162
11. Mangin Jr. E.L., Kugiyama K., Nguy J.H., Kerns S.A., and Henry P.D. Effects of lysolipids and oxidatively modified low density lipoprotein on endothelium-dependent relaxation of rabbit aorta. Circ Res 72 (1993) 161-166
12. Cox D.A., and Cohen M.L. Effects of oxidized low-density lipoprotein on vascular contraction and relaxation: clinical and pharmacological implications in atherosclerosis. Pharmacol Rev 48 (1996) 3-19
13. Tanner F.C., Noll G., Boulanger C.M., and Luscher T.F. Oxidized low density lipoproteins inhibit relaxations of porcine coronary arteries. Role of scavenger receptor and endothelium-derived nitric oxide. Circulation 83 (1991) 2012-2020
14. Hazell L.J., and Stocker R. Oxidation of low-density lipoprotein with hypochlorite causes transformation of the lipoprotein into a high-uptake form for macrophages. Biochem J 290 (1993) 165-172
15. Arnhold J., Wiegel D., Richter O., et al. Modification of low density lipoproteins by sodium hypochlorite. Biomed Biochim Acta 50 (1991) 967-973
16. Liao L., Aw T.Y., Kvietys P.R., and Granger D.N. Oxidized LDL-induced microvascular dysfunction. Dependence on oxidation procedure. Arterioscler Thromb Vasc Biol 15 (1995) 2305-2311
17. (2+)-ATPase activity of human platelets. Cell Calcium 26 (1999) 281-287
18. Volf I., Roth A., Cooper J., Moeslinger T., and Koller E. Hypochlorite modified LDL are a stronger agonist for platelets than copper oxidized LDL. FEBS Lett 483 (2000) 155-159
19. Mulvany M.J., and Halpern W. Mechanical-properties of vascular smooth-muscle cells in situ. Nature 260 (1976) 617-619
20. Heller R., Unbehaun A., Schellenberg B., et al. l-Ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem 276 (2001) 40-47
21. Laggner T., and Goldenberg H. Interaction of respiratory burst and uptake of dehydroascorbic acid in differentiated HL-60 cells. Biochem J 345 (2000) 195-200
22. Vissers M.C.M., and Winterbourn C.C. Oxidative damage to fibronectin. 1. The effects of the neutrophil myeloperoxidase system and HOCl. Arch Biochem Biophys 285 (1991) 53-59
23. Chen S.H., Yang C.Y., Chen P.F., et al. The complete cDNA and amino acid sequence of human apolipoprotein B-100. J Biol Chem 261 (1986) 12918-12921
24. Carr A.C., Tijerina T., and Frei B. Vitamin C protects against and reverses specific hypochlorous acid- and chloramine-dependent modifications of low-density lipoprotein. Biochem J 346 (2000) 491-499
25. Yla Herttuala S. Is oxidized low-density lipoprotein present in vivo?. Curr Opin Lipidol 9 (1998) 337-344
26. Jessup W., Krithairides L., and Stocker R. Lipid oxidation in atherogenesis: an overview. Biochem Soc Trans 32 (2004) 134-138
27. Rikitake Y., Hirata K., Kawashima S., et al. Inhibition of endothelium-dependent arterial relaxation by oxidized phosphatidylcholine. Atherosclerosis 152 (2000) 79-87
28. Heinecke J.W. Mechanisms of oxidative damage of low density lipoprotein in human atherosclerosis. Curr Opin Lipidol 8 (1997) 268-274
29. Heinecke J.W. Mass spectrometric quantification of amino acid oxidation products in proteins: insights into pathways that promote LDL oxidation in the human artery wall. FASEB J 13 (1999) 1113-1120
30. -), a product of the myeloperoxidase system, degrades articular cartilage proteoglycan aggregate. Free Radic Biol Med 10 (1991) 101-109
31. Woods A.A., Linton S.M., and Davies M.J. Detection of HOCl-mediated protein oxidation products in the extracellular matrix of human atherosclerotic plaques. Biochem J 370 (2003) 729-735
32. Hazell L.J., Arnold L., Flowers D., et al. Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J Clin Invest 97 (1996) 1535-1544
33. 2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur J Biochem 267 (2000) 4495-4503
34. Malle E., Wäg G., Thiery J., Sattler W., and Grone H.J. Hypochlorite-modified (lipo)proteins are present in rabbit lesions in response to dietary cholesterol. Biochem Biophys Res Commun 289 (2001) 894-900
35. Zhang C.X., Patel R., Eiserich J.P., et al. Endothelial dysfunction is induced by proinflammatory oxidant hypochlorous acid. Am J Physiol Heart Circ Physiol 281 (2001) H1469-H1475
36. Zhang C.X., Yang J., Jacobs J.D., and Jennings L.K. Interaction of myeloperoxidase with vascular NAD(P)H oxidase-derived reactive oxygen species in vasculature: implications for vascular diseases. Am J Physiol Heart Circ Physiol 285 (2003) H2563-H2572
37. Stocker R., Huang A., Jeranian E., et al. Hypochlorous acid impairs endothelium-derived nitric oxide bioactivity through a superoxide-dependent mechanism. Arterioscler Thromb Vasc Biol 24 (2004) 2028-2033
38. Zhang Z.L., Brennan M.L., Fu X.M., et al. Association between myeloperoxidase levels and risk of coronary artery disease. J Am Med Assoc 286 (2001) 2136-2142
39. Vita J.A., Brennan M.L., Gokce N., et al. Serum Myeloperoxidase levels independently predict endothelial dysfunction in humans. Circulation 110 (2004) 1134-1139
40. Kutter D., Devaquet P., Vanderstocken G., et al. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit?. Acta Haematol 104 (2000) 10-15